85 related articles for article (PubMed ID: 12036925)
1. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
Münster PN; Marchion DC; Basso AD; Rosen N
Cancer Res; 2002 Jun; 62(11):3132-7. PubMed ID: 12036925
[TBL] [Abstract][Full Text] [Related]
2. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.
Da Silva L; Simpson PT; Smart CE; Cocciardi S; Waddell N; Lane A; Morrison BJ; Vargas AC; Healey S; Beesley J; Pakkiri P; Parry S; Kurniawan N; Reid L; Keith P; Faria P; Pereira E; Skalova A; Bilous M; Balleine RL; Do H; Dobrovic A; Fox S; Franco M; Reynolds B; Khanna KK; Cummings M; Chenevix-Trench G; Lakhani SR
Breast Cancer Res; 2010; 12(4):R46. PubMed ID: 20604919
[TBL] [Abstract][Full Text] [Related]
3. A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers.
Amin DN; Ahuja D; Yaswen P; Moasser MM
Mol Cancer Ther; 2015 Dec; 14(12):2805-17. PubMed ID: 26438156
[TBL] [Abstract][Full Text] [Related]
4. A new strategy to ERADicate HER2-positive breast tumors?
Arora S; Golemis EA
Sci Signal; 2015 May; 8(378):fs11. PubMed ID: 26012632
[TBL] [Abstract][Full Text] [Related]
5. HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer.
Mishra R; Kilroy MK; Feroz W; Patel H; Garrett JT
Mol Carcinog; 2024 May; ():. PubMed ID: 38751013
[TBL] [Abstract][Full Text] [Related]
6. Advances in Brain Tumor Therapy Based on the Magnetic Nanoparticles.
Xu S; Zhang G; Zhang J; Liu W; Wang Y; Fu X
Int J Nanomedicine; 2023; 18():7803-7823. PubMed ID: 38144513
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs.
Gámez-Chiachio M; Sarrió D; Moreno-Bueno G
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139701
[TBL] [Abstract][Full Text] [Related]
8. Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance.
Zhang J; Li H; Liu Y; Zhao K; Wei S; Sugarman ET; Liu L; Zhang G
Cells; 2022 Sep; 11(18):. PubMed ID: 36139353
[TBL] [Abstract][Full Text] [Related]
9. Construction of pH/reduction dual responsive MSN-HAgel containing HApt for tumor targeting carriers.
Liu Y; Chen M; Li G; Xu S; Liu H
RSC Adv; 2022 Jun; 12(30):19063-19071. PubMed ID: 35865599
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements.
Akter S; Rahman MA; Hasan MN; Akhter H; Noor P; Islam R; Shin Y; Rahman MDH; Gazi MS; Huda MN; Nam NM; Chung J; Han S; Kim B; Kang I; Ha J; Choe W; Choi TG; Kim SS
Cells; 2022 Feb; 11(4):. PubMed ID: 35203301
[TBL] [Abstract][Full Text] [Related]
11. Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells.
Shen Y; Zhang J; Hao W; Wang T; Liu J; Xie Y; Xu S; Liu H
Int J Nanomedicine; 2018; 13():537-553. PubMed ID: 29416334
[TBL] [Abstract][Full Text] [Related]
12.
Tong J; Tan S; Nikolovska-Coleska Z; Yu J; Zou F; Zhang L
Mol Cancer Ther; 2017 Sep; 16(9):1979-1988. PubMed ID: 28619760
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic Therapy with Hypericin Improved by Targeting HSP90 Associated Proteins.
Solár P; Chytilová M; Solárová Z; Mojžiš J; Ferenc P; Fedoročko P
Pharmaceuticals (Basel); 2011 Nov; 4(11):1488-1502. PubMed ID: 27721334
[TBL] [Abstract][Full Text] [Related]
14. Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis.
Grieve S; Gao Y; Hall C; Hu J; Greer PA
Mol Cell Biol; 2016 Aug; 36(15):2078-88. PubMed ID: 27215381
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.
Jhaveri K; Chandarlapaty S; Iyengar N; Morris PG; Corben AD; Patil S; Akram M; Towers R; Sakr RA; King TA; Norton L; Rosen N; Hudis C; Modi S
Clin Breast Cancer; 2016 Aug; 16(4):276-83. PubMed ID: 26726007
[TBL] [Abstract][Full Text] [Related]
16. Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis.
Roh SH; Kasembeli M; Bakthavatsalam D; Chiu W; Tweardy DJ
Int J Mol Sci; 2015 Nov; 16(11):26706-20. PubMed ID: 26561808
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs.
Lee H; Dam DH; Ha JW; Yue J; Odom TW
ACS Nano; 2015 Oct; 9(10):9859-67. PubMed ID: 26335372
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes.
Ju JH; Oh S; Lee KM; Yang W; Nam KS; Moon HG; Noh DY; Kim CG; Park G; Park JB; Lee T; Arteaga CL; Shin I
Cell Death Differ; 2015 Apr; 22(4):665-76. PubMed ID: 25342465
[TBL] [Abstract][Full Text] [Related]
19. Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition.
Chen Y; Chen J; Yu J; Yang G; Temple E; Harbinski F; Gao H; Wilson C; Pagliarini R; Zhou W
J Biol Chem; 2014 Jul; 289(27):18914-27. PubMed ID: 24831003
[TBL] [Abstract][Full Text] [Related]
20. HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer.
Green AR; Barros FF; Abdel-Fatah TM; Moseley P; Nolan CC; Durham AC; Rakha EA; Chan S; Ellis IO
Breast Cancer Res Treat; 2014 May; 145(1):33-44. PubMed ID: 24706169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
